Torii Pharmaceutical Co., Ltd. currently distributes and markets Riona® Tablets 250mg (generic name in Japan: ferric citrate hydrate, development code: JTT-751, hereinafter "Riona®") for the improvement of hyperphosphatemia in patients with chronic kidney disease, for which Japan Tobacco Inc. (hereinafter "JT") has filed an additional indication for iron deficiency anemia (IDA) (hereinafter the "New Indication"). Torii and ASKA Pharmaceutical Co., Ltd. have entered into a co-promotion agreement that covers this New Indication for Riona®. Under the Agreement, once the New Indication has been approved by PMDA, Torii and ASKA will jointly engage in the marketing of Riona®'s the New Indication.

Torii will mainly focus on medical institutions with chronic kidney disease-related departments, such as nephrology and dialysis, while ASKA will mainly focus on medical institutions with obstetrics and gynecology. As a specialty pharma company that focuses on the obstetrics and gynecology area, ASKA is striving to expand its portfolio of relevant products. Through the co-promotion of Riona®, it will endeavour to further strengthen its presence in the market.

By co-promoting Riona® with ASKA, which has extensive experience in the obstetrics and gynecology area, Torii believes that it will be able to provide wider information about Riona® more effectively for relevant medical professionals.